Description: Rasna Therapeutics, Inc., a biotechnology company, engages in developing targeted drugs to treat diseases in oncology and immunology, primarily focusing on the treatment of leukemia. It is involved in modulating the molecular targets NPM1 and LSD1, which are implicated in the disease progression of leukemia and lymphoma. The company is developing RASP-101, a nanoparticle-based formulation program that focuses on control release of ACT D, which is in Phase II clinical trial to treat Wilm's tumor, Ewing's Sarcoma, Metastatic Nonseminomatous Testicular cancer, Gestational Trophoblastic Neoplastic, childhood Rhabdomyosarcoma, and Regional Perfusion in locally recurrent and locoregional solid malignancies under the Cosmegen trade name. It is also developing RASP-201 (LSD1) an enzyme that demethylates lysine side chain of histones; and RASP-301, an NPM1 gene that provides instructions for making a nucleophosmin protein. The company was founded in 2013 and is headquartered in New York, New York.
Home Page: www.rasna.com
420 Lexington Avenue
New York,
NY
10170
United States
Phone:
646 396 4087
Officers
| Name | Title |
|---|---|
| Ms. Keeren Shah | Fin. Director |
| Mr. Willy Jules Simon | Exec. Chairman |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.3116 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | September |
| Full Time Employees: | 0 |